Literature DB >> 25875972

Diagnostic Accuracy of Preoperative Gadoxetic Acid-enhanced 3-T MR Imaging for Malignant Liver Lesions by Using Ex Vivo MR Imaging-matched Pathologic Findings as the Reference Standard.

Eduardo A C Costa1, Guilherme M Cunha1, Emmanuil Smorodinsky1, Irene Cruite1, An Tang1, Robert M Marks1, Lisa Clark1, Tanya Wolfson1, Anthony Gamst1, Jason K Sicklick1, Alan Hemming1, Michael R Peterson1, Michael S Middleton1, Claude B Sirlin1.   

Abstract

PURPOSE: To determine per-lesion sensitivity and positive predictive value (PPV) of gadoxetic acid-enhanced 3-T magnetic resonance (MR) imaging for the diagnosis of malignant lesions by using matched (spatially correlated) hepatectomy pathologic findings as the reference standard. Materials and
METHODS: In this prospective, institutional review board-approved, HIPAA-compliant study, 20 patients (nine men, 11 women; mean age, 59 years) with malignant liver lesions who gave written informed consent underwent preoperative gadoxetic acid-enhanced 3-T MR imaging for surgical planning. Two image sets were independently analyzed by three readers to detect liver lesions (set 1 without and set 2 with hepatobiliary phase [HBP] images). Hepatectomy specimen ex vivo MR imaging assisted in matching gadoxetic acid-enhanced 3-T MR imaging findings with pathologic findings. Interreader agreement was assessed by using the Cohen κ coefficient. Per-lesion sensitivity and PPV were calculated.
RESULTS: Cohen κ values were 0.64-0.76 and 0.57-0.84, and overall per-lesion sensitivity was 45% (42 of 94 lesions) to 56% (53 of 94 lesions) and 58% (55 of 94 lesions) to 64% (60 of 94 lesions) for sets 1 and 2, respectively. The addition of HBP imaging did not affect interreader agreement but significantly improved overall sensitivity for one reader (P < .05) and almost for another (P = .05). Sensitivity for 0.2-0.5-cm lesions was 0% (0 of 26 lesions) to 8% (two of 26 lesions) for set 1 and 4% (one of 26 lesions) to 12% (three of 26 lesions) for set 2. Sensitivity for 0.6-1.0-cm lesions was 28% (nine of 32 lesions) to 59% (19 of 32 lesions) for set 1 and 66% (21 of 32 lesions) to 69% (22 of 32 lesions) for set 2. Sensitivity for lesions at least 1.0 cm in diameter was at least 81% (13 of 16 lesions) for set 1 and was not improved for set 2. PPV was 98% (56 of 57 lesions) to 100% (60 of 60 lesions) for all readers without differences between image sets or lesion size.
CONCLUSION: Gadoxetic acid-enhanced 3-T MR imaging provides high per-lesion sensitivity and PPV for preoperative malignant liver lesion detection overall, although sensitivity for 0.2-0.5-cm malignant lesions is poor.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25875972      PMCID: PMC4962530          DOI: 10.1148/radiol.2015142069

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  20 in total

1.  High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla.

Authors:  Scott K Nagle; Reed F Busse; Anja C Brau; Jean H Brittain; Alex Frydrychowicz; Yuji Iwadate; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-05-30       Impact factor: 4.813

2.  Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?

Authors:  Mustafa R Bashir; Rajan T Gupta; Matthew S Davenport; Brian C Allen; Tracy A Jaffe; Lisa M Ho; Daniel T Boll; Elmar M Merkle
Journal:  J Magn Reson Imaging       Date:  2012-09-25       Impact factor: 4.813

3.  Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging.

Authors:  D Löwenthal; M Zeile; W Y Lim; C Wybranski; F Fischbach; G Wieners; M Pech; S Kropf; J Ricke; O Dudeck
Journal:  Eur Radiol       Date:  2010-10-02       Impact factor: 5.315

4.  Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT.

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Hiroyuki Morisaka; Hironobu Sou; Ali Muhi; Kazufumi Kimura; Katsuhiro Sano; Tsutomu Araki
Journal:  Radiology       Date:  2011-06-21       Impact factor: 11.105

5.  Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI.

Authors:  Ali Muhi; Tomoaki Ichikawa; Utaroh Motosugi; Hironobu Sou; Hiroto Nakajima; Katsuhiro Sano; Mika Sano; Satoshi Kato; Takatoshi Kitamura; Zareen Fatima; Kimiyo Fukushima; Hiroshi Iino; Yoshiyuki Mori; Hideki Fujii; Tsutomu Araki
Journal:  J Magn Reson Imaging       Date:  2011-08       Impact factor: 4.813

6.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

7.  Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients: a multicenter, open-label, phase III study.

Authors:  Meng-Su Zeng; Hui-Yi Ye; Liang Guo; Wei-Jun Peng; Jian-Ping Lu; Gao-Jun Teng; Yi Huan; Ping Li; Jian-Rong Xu; Chang-Hong Liang; Josy Breuer
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2013-12

8.  Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think...

Authors:  Dominique Elias; Jérémie H Lefevre; Pierre Duvillard; Diane Goéré; Clarisse Dromain; Frédéric Dumont; Eric Baudin
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

9.  Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.

Authors:  Renate Hammerstingl; Alexander Huppertz; Josy Breuer; Thomas Balzer; Anthony Blakeborough; Rick Carter; Lluis Castells Fusté; Gertraud Heinz-Peer; Werner Judmaier; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Müller; Koenraad Mortelè; Peter Reimer; Maximilian F Reiser; Philip J Robinson; Kohkan Shamsi; Michael Strotzer; Matthias Taupitz; Bernd Tombach; Gianluca Valeri; Bernhard E van Beers; Thomas J Vogl
Journal:  Eur Radiol       Date:  2007-12-06       Impact factor: 5.315

Review 10.  Hepatocellular carcinoma in advanced liver cirrhosis: CT detection in transplant patients.

Authors:  J H Lim; C K Park
Journal:  Abdom Imaging       Date:  2004 Mar-Apr
View more
  4 in total

1.  Radiologic-pathologic correlation of lesions in resected liver specimens with an ex vivo MRI-compatible localization device.

Authors:  Victoria R Rendell; Emily R Winslow; Timothy J Colgan; S Krisztian Kovacs; Matthias R Mühler; Gesine Knobloch; Agnes G Loeffler; Rashmi M Agni; Scott B Reeder
Journal:  Eur Radiol       Date:  2022-07-21       Impact factor: 7.034

2.  Convolutional neural network-automated hepatobiliary phase adequacy evaluation may optimize examination time.

Authors:  Guilherme Moura Cunha; Kyle A Hasenstab; Atsushi Higaki; Kang Wang; Timo Delgado; Ryan L Brunsing; Alexandra Schlein; Armin Schwartzman; Albert Hsiao; Claude B Sirlin; Katie J Fowler
Journal:  Eur J Radiol       Date:  2020-01-14       Impact factor: 3.528

3.  Evaluation of tongue squamous cell carcinoma resection margins using ex-vivo MR.

Authors:  Stefan C A Steens; Elise M Bekers; Willem L J Weijs; Geert J S Litjens; Andor Veltien; Arie Maat; Guido B van den Broek; Jeroen A W M van der Laak; Jürgen J Fütterer; Christina A Hulsbergen van der Kaa; Matthias A W Merkx; Robert P Takes
Journal:  Int J Comput Assist Radiol Surg       Date:  2017-01-27       Impact factor: 2.924

4.  Limited detection of small (≤ 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection.

Authors:  Yousun Ko; Jihang Kim; Joseph Kyu-Hyung Park; Haeryoung Kim; Jai Young Cho; Sung-Bum Kang; Soyeon Ahn; Kyong Joon Lee; Kyoung Ho Lee
Journal:  PLoS One       Date:  2017-12-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.